Comparison of the effect of rosuvastatin versus rosuvastatin/ezetimibe on markers of inflammation in patients with acute myocardial infarction.

Exp Ther Med · 2017 · PMC5704334 · PMID 29201198

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) study demonstrated that the reduction in Lp-PLA2 activity during the first year of treatment was a highly significant predictor of coronary heart disease events, independent of any change in LDL-C, and may account for over half of the benefits of pravastatin ( 16 ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.